fda warning letter hims compounded semaglutide september 2025 15, 2025: Telehealth company must stop implying its GLP-1 is FDA-approved, warns – Partnership for Safe Medicines Hims: Why The Semaglutide Shortage

These include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (very common) Vomiting (common, affecting up to 1 in 10 people) Constipation (common) Abdominal pain (common) Reduced appetite (very common) These gastrointestinal effects typically occur during dose escalation and often diminish over time as the body adjusts to the medication

The downsides of GLP-1s can be summed up in one message: You dont know what youre getting

It's everywhere right now

14.4 Cardiovascular Outcomes Trial of RYBELSUS in Adult Patients with Type 2 Diabetes Mellitus and High Risk of Having a Cardiovascular Event Trial 7 [Semaglutide Cardiovascular Outcomes Trial (SOUL), NCT03914326] was a randomized, double-blind, parallel-group, placebo-controlled trial

Fainting, collapse, or loss of consciousness

Mounjaro Weight Loss Plateau: Causes and Solutions Experiencing a weight loss plateau whilst taking Mounjaro (tirzepatide) is a common and often frustrating challenge